Cytokinetics
CYTK
$62.91
+1.45%
Cytokinetics Inc. is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors for debilitating diseases in which muscle performance is compromised, including hypertrophic cardiomyopathy (HCM), amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company has transitioned from a pure clinical-stage developer into a commercial-stage organization following the approval of MYQORZO (aficamten), an allosteric and reversible inhibitor of cardiac myosin motor activity, positioning it as a direct competitor to Bristol Myers Squibb's Camzyos in the cardiac myosin inhibitor market. The current investor narrative centers on the commercial launch trajectory of MYQORZO, with recent headlines debating whether aficamten can capture significant HCM market share and strengthen Cytokinetics' growth prospects against entrenched competition. At the same time, the stock has been under pressure, with shares declining sharply over the past three months as investors weigh launch execution risk, persistent cash burn, and the company's ability to convert a promising pipeline into durable revenue.…
CYTK
Cytokinetics
$62.91
Related headlines
Investment Opinion: Should I buy CYTK Today?
The synthesized recommendation is Hold, balancing the strong analyst consensus (strong_buy, average target $109.95) against the extreme valuation and execution risks. The core thesis is that MYQORZO's commercial ramp could drive substantial upside, but the current price already discounts a near-flawless launch, and the company's cash burn necessitates further dilution. The analyst consensus implies 74.8% upside, but the risk/reward is skewed by the binary nature of the launch.
Supporting evidence includes the sequential revenue growth from $19.36 million in Q1 2026 to $31.91 million in Q2 2026, the high gross margin of 91.4%, and the strong liquidity with a current ratio of 4.53. However, the trailing PS of 86.62x and EV/Sales of 131.22x are exorbitant compared to the sector, and the TTM free cash flow of -$580.71 million highlights the cash burn. The forward PS of ~3.3x, based on the $2.29 billion revenue estimate, is reasonable if the launch succeeds, but the gap between trailing and forward expectations is enormous.
Key risks that could invalidate the thesis include slower-than-expected MYQORZO adoption due to Camzyos competition, further equity dilution to fund operations, and potential pipeline setbacks. The rating would upgrade to Buy if MYQORZO revenue exceeds $50 million quarterly with improving cash burn, or downgrade to Sell if revenue growth stalls or cash reserves fall below $100 million. Relative to its history and peers, the stock appears overvalued on trailing metrics but potentially undervalued on forward estimates, making it a high-risk, high-reward proposition.
Sign up to view all
CYTK 12-Month Price Forecast
The forward-looking view is cautiously neutral, as the potential for MYQORZO to transform Cytokinetics into a profitable commercial-stage biotech is offset by extreme valuation and cash burn. The sequential revenue growth and high gross margin are encouraging, but the trailing PS of 86.62x and negative free cash flow of $580.71M highlight the risks. Analyst sentiment is overwhelmingly bullish, but the wide target range ($85-$146) reflects high uncertainty. An upgrade to bullish would require sustained MYQORZO revenue growth above $50 million quarterly and a clear path to profitability, while a downgrade to bearish would occur if revenue stalls or cash reserves deplete below $100 million.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cytokinetics's 12-month outlook, with a consensus price target around $109.95 and implied upside of +74.8% versus the current price.
Average Target
$109.95
0 analysts
Implied Upside
+74.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$85 - $146
Analyst target range
Cytokinetics is covered by 20 analysts with a consensus recommendation of "strong_buy" (recommendation mean of 1.5 on a 1-5 scale where 1 is Strong Buy), reflecting overwhelmingly bullish sentiment despite the stock's recent weakness. The average target price of $109.95 implies +74.8% upside from the current price of $62.91, a remarkably wide gap that suggests analysts believe the market is significantly mispricing the stock's prospects. The consensus leans strongly bullish, with the Buy/Hold/Sell distribution heavily skewed toward Buy ratings, and the estimated EPS average of $3.85 for the forward period implies a dramatic profitability inflection that would justify the premium valuation if delivered.
The target price range spans from a low of $85.00 to a high of $146.00, a spread of $61.00 (or 71.8% of the low target), which signals high uncertainty about the company's future trajectory. The high target of $146 likely assumes rapid MYQORZO market share gains, successful pipeline readouts, and multiple expansion as the company transitions to sustained profitability, while the low target of $85 still implies +35.1% upside and probably prices in slower launch execution and continued cash burn but no fundamental collapse. Institutional ratings show a pattern of stability with no recent downgrades; UBS upgraded from Neutral to Buy on June 29, 2026, and firms including HC Wainwright, JP Morgan, Barclays, Truist, RBC, Citizens, Needham, and Mizuho have maintained bullish ratings through August 2026. The wide target spread and unanimous bullishness suggest that analysts are aligned on the long-term opportunity but diverge significantly on the timing and magnitude of the commercial ramp, making this a high-conviction but high-variance situation for investors.
Bulls vs Bears: CYTK Investment Factors
The bear case currently has stronger evidence due to the extreme trailing valuation (PS 86.6x), severe cash burn (-$580.7M TTM FCF), and negative profitability (-622.8% net margin), which are concrete and immediate. However, the bull case rests on the forward revenue inflection: analysts project $2.29B in revenue, which would collapse the forward PS to ~3.3x, and the consensus strong_buy with a $109.95 average target implies 74.8% upside. The single most important tension is whether MYQORZO can scale rapidly enough to justify the valuation before cash reserves deplete, as the company's $258.38M cash balance and negative operating cash flow make the launch trajectory existential. If the commercial ramp accelerates, the stock could re-rate sharply; if it stalls, the downside to the 52-week low of $54.30 is significant.
Bullish
- Analyst Consensus Strong Buy: 20 analysts rate CYTK a consensus strong_buy (mean 1.5), with an average target price of $109.95 implying 74.8% upside from the current $62.91. Even the lowest target of $85.00 implies 35.1% upside, suggesting the selloff is overdone relative to fundamental expectations.
- MYQORZO Launch Ramping Sequentially: Q2 2026 revenue rose to $31.91 million from $19.36 million in Q1 2026, driven by $25.33 million in net product revenue from MYQORZO. Gross margin also improved sequentially from 87.6% to 91.4%, indicating early commercial traction and manufacturing efficiency.
- Massive Forward Revenue Growth Expected: Analysts project average forward revenue of $2.29 billion, which would represent roughly 72x growth from the current quarterly run-rate. At the current market cap of $7.63 billion, this implies a forward PS of only ~3.3x, a reasonable multiple if the launch succeeds.
- Strong Balance Sheet Liquidity: The current ratio of 4.53 and quick ratio of 6.66 provide ample short-term liquidity. Cash stood at $258.38 million at the end of Q2 2026, up from $132.95 million, after a $798.15 million equity raise, giving the company runway to fund the launch.
Bearish
- Extreme Valuation on Trailing Metrics: The trailing PS ratio is 86.62x and EV/Sales is 131.22x, versus typical large-cap biotech multiples of 4-8x sales. This massive premium leaves no room for execution missteps and prices in flawless commercial execution.
- Severe Cash Burn and Negative Cash Flow: TTM free cash flow is -$580.71 million, with Q2 2026 free cash flow of -$164.17 million. The company relied on $798.15 million in common stock issuance in Q2 2026 to fund operations, and further dilution is likely.
- Revenue Declining Year-over-Year: Q2 2026 revenue of $31.91 million fell 52.2% from $66.77 million in Q2 2025, though the prior year included a large collaboration milestone. The underlying product revenue ramp remains early-stage relative to the $7.6 billion market cap.
- Deeply Negative Profitability: Q2 2026 net loss was $198.76 million, with a net margin of -622.8% and operating margin of -551.1%. Operating expenses of $205.07 million, including $97.81 million in R&D and $104.40 million in SG&A, continue to outpace revenue.
CYTK Technical Analysis
Cytokinetics is in a corrective downtrend within a longer-term recovery structure, with the current price of $62.91 sitting just 9.7% above its 52-week low of $54.30 and 28.8% below its 52-week high of $88.31, placing it at roughly 25.5% of its 52-week range. The 1-year price change of +4.31% masks significant deterioration, as the stock has given back nearly all of its gains from the mid-year rally that peaked near $87 in late June. This positioning near the lower quartile of the annual range suggests the stock is in a vulnerable zone where momentum has clearly broken down, though the proximity to the 52-week low could attract value-oriented buyers if support holds. The relative strength versus SPY over the past year is -11.69%, confirming meaningful underperformance against the broader market.
Recent momentum is decisively negative and accelerating to the downside, with a 1-month decline of -15.11% and a 3-month decline of -25.87%, both far worse than the S&P 500's respective +2.12% and +3.13% gains over the same periods. The relative strength readings of -17.23% (1-month) and -29.00% (3-month) highlight severe divergence from the market, signaling that this is a stock-specific selloff rather than a broad market phenomenon. The 6-month change of -3.23% versus the 1-year change of +4.31% indicates that the bulk of the annual gain was front-loaded in late 2025 and early 2026, with the subsequent decline erasing most of that progress. The most recent session showed a modest +1.45% bounce on volume of approximately 1.12 million shares, but this appears to be a technical rebound within a broader downtrend rather than a trend reversal signal.
Key technical support rests at the 52-week low of $54.30, which represents a critical line in the sand; a breakdown below this level would likely trigger momentum-driven selling and open the door to new multi-year lows. Resistance is established at the 52-week high of $88.31, and the stock would need to reclaim the $75-$80 zone (the August consolidation area) before any credible challenge of that high becomes feasible. The beta of 0.408 is notably low, indicating the stock is roughly 60% less volatile than the broader market on a systematic basis, which is unusual for a commercial-stage biotech and may reflect the stock's idiosyncratic, news-driven trading patterns rather than broad market sensitivity. The maximum drawdown of -29.96% over the period underscores the severity of the current correction and the importance of disciplined position sizing for anyone considering entry at these levels.
Beta
0.41
0.41x market volatility
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
$54-$88
Price range past year
Annual Return
+4.3%
Cumulative gain past year
| Period | CYTK Return | S&P 500 |
|---|---|---|
| 1m | -15.1% | +1.9% |
| 3m | -25.9% | +3.9% |
| 6m | -3.2% | +12.1% |
| 1y | +4.3% | +19.2% |
| ytd | +1.9% | +14.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CYTK Fundamental Analysis
Cytokinetics' revenue trajectory is highly volatile and currently contracting on a year-over-year basis, with Q2 2026 revenue of $31.91 million representing a -52.2% decline from Q2 2025's $66.77 million. The sequential trend is more constructive, with revenue rising from $19.36 million in Q1 2026 to $31.91 million in Q2 2026, driven primarily by net product revenue of $25.33 million (MYQORZO launch) and collaboration revenues of $3.29 million. However, the prior-year comparison is distorted by a large collaboration milestone in Q2 2025, and the underlying product revenue ramp remains early-stage relative to the company's $7.6 billion market cap. The key question for investors is whether MYQORZO can scale rapidly enough to justify the current valuation, particularly given the competitive threat from Camzyos and the need to build out commercial infrastructure.
Profitability remains deeply negative, with a Q2 2026 net loss of $198.76 million and a net margin of -622.8%, reflecting the heavy cost structure of a commercial-stage biotech investing in launch execution and pipeline development. Gross margin is exceptionally high at 91.4% on a quarterly basis (88.5% on a TTM basis), which is typical for a biotech with a proprietary drug, but this is more than offset by operating expenses of $205.07 million, including $97.81 million in R&D and $104.40 million in SG&A. The operating margin of -551.1% and EBITDA of -$191.75 million illustrate the scale of losses, though the sequential improvement in gross margin from 87.6% in Q1 2026 to 91.4% in Q2 2026 suggests early manufacturing efficiencies are emerging as volumes scale.
The balance sheet shows a current ratio of 4.53 and a quick ratio of 6.66, indicating strong short-term liquidity, but the company is burning cash at an alarming rate with TTM free cash flow of -$580.71 million and Q2 2026 free cash flow of -$164.17 million. The debt-to-equity ratio of -1.95 is negative due to negative shareholders' equity, and the company relied on $798.15 million in common stock issuance during Q2 2026 to fund operations, highlighting its dependence on external financing. Cash at the end of Q2 2026 stood at $258.38 million, up from $132.95 million at the start of the quarter, but this was entirely due to the equity raise rather than operating cash generation. The ROE of 1.19 is not meaningful given the negative equity base, and the cash flow to debt ratio of -0.126 signals that operating cash flows are insufficient to service debt obligations, making future capital raises likely.
Quarterly Revenue
$31914000.0B
2026-06
Revenue YoY Growth
-52.2%
YoY Comparison
Gross Margin
91.4%
Latest Quarter
Free Cash Flow
$-580714999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CYTK Overvalued?
Because Cytokinetics reported negative net income (TTM EPS of -$0.10 and Q2 2026 net loss of $198.76 million), the PE ratio is not meaningful and I have selected the PS ratio as the primary valuation metric, supplemented by EV/Sales. The trailing PS ratio stands at 86.62x, while the EV/Sales ratio is 131.22x, both extraordinarily high for a company with declining year-over-year revenue. The forward PE of -14.15 remains negative, but the analyst estimated EPS average of $3.85 for the forward period implies the market expects a dramatic swing to profitability, which would represent a transformational inflection if achieved.
Relative to the biotechnology sector, where profitable large-cap biotechs typically trade at 4-8x sales and even high-growth commercial-stage peers rarely exceed 15-20x, Cytokinetics' PS of 86.62x represents a massive premium of roughly 10-20x the sector norm. This premium is only justifiable if one believes the forward revenue estimate of $2.29 billion (analyst average) is achievable, which would imply a forward PS of approximately 3.3x at the current market cap of $7.63 billion. The gap between trailing and forward revenue expectations is enormous, reflecting the market's bet that MYQORZO will scale rapidly, but the current multiple leaves little room for execution missteps.
Historically, Cytokinetics' PS ratio has been extremely volatile, ranging from 37.86x in Q2 2022 to over 13,420x in Q3 2024 when revenue was negligible, and the current 86.62x is actually near the lower end of its 3-year range on a trailing basis. However, this historical context is less relevant now that the company has a commercial product, and the more appropriate comparison is to the forward PS of 3.3x, which would be reasonable if revenue targets are met. The PB ratio of -11.56 is negative due to negative book value and is not informative; the PEG ratio of -0.40 is also not meaningful given negative earnings. The key valuation risk is that the market is pricing in flawless execution of a launch that faces formidable competition from an entrenched incumbent.
PE
-9.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-11.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are severe. Cytokinetics burned $580.71 million in TTM free cash flow and $164.17 million in Q2 2026 alone, with a net loss of $198.76 million in the quarter. The company has negative shareholders' equity (debt-to-equity of -1.95) and relied on a $798.15 million equity raise in Q2 2026 to fund operations, meaning further dilution is highly probable. Revenue is concentrated in a single product, MYQORZO, which generated $25.33 million in Q2 2026, and the year-over-year revenue decline of 52.2% highlights the volatility and dependence on successful commercialization.
Market and competitive risks are equally daunting. The trailing PS ratio of 86.62x and EV/Sales of 131.22x represent a massive premium to the biotech sector, where profitable large-caps trade at 4-8x sales. This valuation leaves no margin for error and exposes the stock to severe multiple compression if growth disappoints. Competition from Bristol Myers Squibb's Camzyos, an entrenched cardiac myosin inhibitor, threatens MYQORZO's market share, as highlighted by recent news debating whether aficamten can capture significant HCM market share. The low beta of 0.408 suggests the stock is less sensitive to broad market moves, but its idiosyncratic, news-driven volatility is high, with a 3-month decline of 25.87% versus the S&P 500's +3.13% gain.
The worst-case scenario involves MYQORZO failing to gain traction against Camzyos, leading to revenue missing the $2.29 billion analyst estimate, which would trigger a collapse in the forward valuation and force additional dilutive financing. In this scenario, the stock could retest its 52-week low of $54.30, representing a 13.7% decline from the current $62.91, or fall further to the analyst low target of $85.00? No, the analyst low is $85, which is above current price, so the downside is to the 52-week low. A more severe case could see the stock break below $54.30 and approach the maximum drawdown of -29.96%, implying a price near $44.00, a 30% loss from current levels. The combination of cash burn, competitive pressure, and valuation risk makes this a high-risk investment.
FAQ
The most severe risk is financial: TTM free cash flow of -$580.71 million and a Q2 2026 net loss of $198.76 million, with reliance on equity raises ($798.15 million in Q2 2026) that dilute shareholders. Competitive risk is high, as Bristol Myers Squibb's Camzyos is an entrenched competitor in the HCM market. Valuation risk is extreme, with a trailing PS of 86.62x that could compress sharply if growth disappoints. Finally, company-specific risk includes pipeline failures in ALS or heart failure, which could further pressure the stock.
The 12-month forecast includes a bull case (30% probability) with a target range of $109.95-$146.00, a base case (50% probability) of $85.00-$109.95, and a bear case (20% probability) of $54.30-$85.00. The base case is most likely, assuming moderate MYQORZO adoption and continued cash burn but no major setbacks. The key assumption is that MYQORZO revenue reaches at least $1.76 billion by mid-2027, aligning with the low end of analyst estimates. If revenue exceeds expectations, the bull case could materialize; if it disappoints, the bear case is likely.
On trailing metrics, CYTK is significantly overvalued, with a PS ratio of 86.62x and EV/Sales of 131.22x, compared to the biotech sector average of 4-8x sales. However, on a forward basis, the estimated revenue of $2.29 billion implies a forward PS of only ~3.3x, which would be reasonable if the launch succeeds. The market is pricing in flawless execution of MYQORZO, leaving little room for error. Thus, the stock is overvalued relative to current financials but potentially undervalued if forward estimates are met.
CYTK presents a high-risk, high-reward opportunity that may be suitable for aggressive investors. The analyst consensus is strong_buy with an average target of $109.95, implying 74.8% upside, but the trailing PS of 86.62x and TTM free cash flow of -$580.71 million highlight significant risks. The biggest downside risk is a failed commercial launch, which could send the stock to its 52-week low of $54.30, a 13.7% decline. For those with a high risk tolerance and a long-term horizon, a small position could be justified, but it is not a good buy for conservative investors.
CYTK is more suitable for long-term investment, given its commercial-stage transition and the multi-year potential of MYQORZO. The stock's beta of 0.408 indicates lower market volatility, but its idiosyncratic risk is high, with a 3-month decline of 25.87%. There is no dividend, and earnings visibility is low, making it unsuitable for short-term trading unless one is speculating on binary events. A minimum holding period of 2-3 years is recommended to allow the commercial launch to mature and the pipeline to progress.